OXavidin for Tissue Targeting Biotinylated Therapeutics
Table 1
Setting up production method of OXavidin.
NaIO4 mM
CHO/Avidin molar ratio SD
ST2210 binding SD
Tissue residence % ID/100 mg SD
()
()
24 hours ()
1 week ()
Avidin
—
LoQ
00
2.2 0.4
0.5 0.1
(5)
(7)
(5)
Oxidized avidin
1
5.6 0.8
77.2 0.9
3.1 0.7
0.16 0.03
(5)
(4)
(1)
(1)
5
7.5 0.8
55.7 2.2
6.3 0.3
0.99 0.25
(5)
(4)
(1)
(1)
10
8.4 1.0
50.9 2.4
18.0 2.5
9.7 3.2
(6)
(6)
(4)
(3)
20
11.5 1.5*
49.1 2.1
19.1 2.0
11.4 1.3
(7)
(6)
(4)
(3)
40
10.9 2.6
44.5 0.9
NT
NT
(5)
(4)
HABA
OXavidin
1
4.0 0.8
99.0 0.2
NT
NT
(3)
(3)
5
7.1 1.6
95.0 1.7
NT
NT
(4)
(3)
10
8.5 1.3
86.3 ±1.6**
16.2 ±2.3
9.9 ±1.3
(5)
(3)
(4)
(4)
20
12.9 2.3#
81.4 1.0#**
18.7 1.1
11.7 1.7
(6)
(4)
(5)
(5)
40
9.8 1.9
73.0 0.6
NT
NT
(4)
(3)
: Number of independent experiments; SD: Standard Deviation; NT: Not tested. @The experimental value of 97.4 0.5% obtained with ST2210 compared to free biotin by HABA assay is assumed as 100% reference value for modified avidins; versus 10 mM; versus 10 mM (One way Anova followed by Student-Newman-Keuls); versus same without HABA (Two-way Anova followed by Bonferroni).
